Log In
Print this Print this

serelaxin (Reasanz) (RLX030) (formerly ConXn)

Also known as: Relaxin

  Manage Alerts
Collapse Summary General Information
Company Novartis AG
DescriptionRecombinant human relaxin 2 (RLN2; H2)
Molecular Target Relaxin 2 (RLN2) (H2)
Mechanism of ActionRelaxin receptor agonist
Therapeutic ModalityBiologic: Protein
Latest Stage of DevelopmentRegistration
Standard IndicationHeart failure
Indication DetailsTreat acute heart failure (AHF)
Regulatory Designation U.S. - Breakthrough Therapy (Treat acute heart failure (AHF));
EU - Standard Review (Treat acute heart failure (AHF))
Partner Endo International plc; GlaxoSmithKline plc

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments





 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today